Neurocrine Biosciences Increases FY23 Ingrezza Net Product Sales Guidance To 1.82B-$1.84B From Prior Guidance Of $1.77B-$1.82B
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences has increased its FY23 Ingrezza net product sales guidance to $1.82B-$1.84B, up from the previous guidance of $1.77B-$1.82B.
October 31, 2023 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences has raised its FY23 Ingrezza net product sales guidance, which could positively impact its stock price.
Neurocrine Biosciences has increased its sales guidance for FY23, indicating that the company expects higher sales than previously forecasted. This is generally seen as a positive sign by investors and could lead to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100